Have any questions? 706-721-6582 or cts@augusta.edu
- Connect® MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry
Clinical Trial
Connect® MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry
This study is observational. An observational disease registry study means that only information about your disease and medical treatment that your study doctor is already prescribing as part of your standard medical care is collected. Standard medical care is the treatment normally given for a certain condition or illness.The registry will collect information from patient's regular care medical records for review and study: patient's medical history and medications, cancer treatment and side effects, the results of patient's regular care laboratory tests, and the results of cancer care and treatment procedures performed as part of regular care. The registry that will be built from information gathered from this study can help doctors decide what to do in situations when a new treatment is needed. Importantly, they can also gather information to help doctors learn which treatments are most effective in these situations. You will continue with your standard medical care and continue with any medicines you are now taking, office visits and laboratory testing according to the normal routine practices of your treating or study doctor(s). No additional medication, or payment for medication, is provided as part of this study. There is no investigational drug involved in this study. There will be no additional study visits, procedures, or testing required for this study. We will only collect this information as it relates to the standard medical care you are receiving.
- Circulatory System
- Lymphatic System
- Acute Myeloid Leukemia (AML)
- Idiopathic Cytopenia Of Undetermined Significance (ICUS)
- Leukemia
- Myelodisplastic Syndrome (MDS)
Eligibility Criteria
- Patient has been newly diagnosed, which means patient showing signs and symptoms of the disease, with either: Myelodisplastic Syndrome (MDS) and are at least 18 years of age; or Idiopathic Cytopenia of Undetermined Significance (ICUS) and are at least 18 years of age; or Acute Myeloid Leukemia (AML) and are at least 55 years of age Patient is willing and able to provide signed informed consent. Patient understands that he/she is being asked to participate in an observational study and agrees to participate. Patient agrees to complete health and quality of life questionnaires asking how he/she has been feeling since the diagnosis with MDS, ICUS or AML. These questionnaires are simple and brief and typically take 10-15 minutes to complete